FAQ: Quantum BioPharma's Health Canada Product License for Qlarity

What is the main announcement from Quantum BioPharma Ltd.?

Quantum BioPharma Ltd. has received a Product License (PN 80144141) from Health Canada for its natural health product Qlarity, permitting its sale in Canada with recommended uses including supporting energy production, metabolism, electrolyte balance, mental alertness, cognitive performance, endurance, and fatigue reduction.

Why is this Product License significant for Quantum BioPharma?

This license allows Quantum BioPharma to sell Qlarity in Canada, expanding its market reach following the previous licensing of a similar product in the United States under the brand name unbuzzd™, thereby increasing potential revenue streams and market presence.

What are the recommended uses for Qlarity as approved by Health Canada?

Health Canada has approved Qlarity for recommended uses including supporting energy production, metabolism, electrolyte balance, mental alertness, cognitive performance, endurance, and fatigue reduction.

How does Qlarity relate to Quantum BioPharma’s other product, unbuzzd™?

Qlarity is a natural health product similar to unbuzzd™, which Quantum previously licensed in the United States, indicating the company’s strategy to market comparable products under different brands in various regions.

What is Quantum BioPharma’s focus beyond natural health products?

Quantum BioPharma is dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders, with drug candidates in different stages of development.

Who owns the rights to unbuzzd™ and what are the financial arrangements?

Quantum BioPharma spun out the OTC version of unbuzzd™ to Unbuzzd Wellness Inc., retaining 20.11% ownership as of March 31, 2025, and receives royalty payments of 7% of sales until payments total $250 million, after which it drops to 3% in perpetuity.

Where can investors find the latest news and updates about Quantum BioPharma?

The latest news and updates relating to QNTM are available in the company’s newsroom at https://www.investorbrandnetwork.com/clients/quantum-biopharma-ltd/.

What is Lucid-MS and how does it fit into Quantum BioPharma’s portfolio?

Lucid-MS is Quantum BioPharma’s lead compound, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models, developed through its wholly owned subsidiary Lucid Psycheceuticals Inc.